<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133302</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG9809</org_study_id>
    <secondary_id>C000000036</secondary_id>
    <nct_id>NCT00133302</nct_id>
  </id_info>
  <brief_title>Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)</brief_title>
  <official_title>Randomized Phase III Study of Standard CHOP (S-CHOP) Versus Biweekly CHOP (Bi-CHOP) in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the clinical benefit of the dose intensified
      regimen, Bi-CHOP in comparison to standard CHOP for advanced intermediate or high grade
      non-Hodgkin's lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of JCOG9809 was to determine whether treatment results of aggressive NHL could be
      improved by shortening intervals of CHOP chemotherapy with the prophylactic use of G-CSF. The
      primary endpoint was Progression Free Survival (PFS), and the planned accrual was 450. Until
      December, 2002, 323 patients with advanced aggressive NHL were randomized to standard CHOP
      arm (CHOP x 8, every three weeks) and biweekly CHOP arm (CHOP x 8, every two weeks).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 1999</start_date>
  <completion_date>February 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment>450</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard CHOP</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bi-CHOP (dose intensified CHOP)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermediate- or high-grade non-Hodgkin's lymphoma, excluding cutaneous t-cell
             lymphoma (CTCL), adult T-cell leukemia-lymphoma (ATL) and T-cell lymphoblastic
             lymphoma (T-LbL) (Working Formulation)

          -  Ann Arbor stage: II, III, IV

          -  No prior chemotherapy or radiotherapy

          -  Age: 15 to 69

          -  Performance status (PS): 0, 1, 2

          -  WBC &gt;= 3,000 /mm3, ANC &gt;= 1,200 /mm3, Platelet &gt;= 75,000 /mm3

          -  GOT/GPT &lt;= 5 x Normal Upper Limit, T-Bil &lt;= 2.0 mg/dL

          -  Creatinine &lt;= 2.0 mg/dL

          -  Normal ECG, Ejection Fraction &gt;= 50%

          -  PaO2 &gt;= 65 mmHg

          -  Written informed consent

        Exclusion Criteria:

          -  Uncontrollable diabetes mellitus

          -  Severe complication (infection, heart failure, renal failure, liver failure, etc)

          -  Anamnesis of heart disease

          -  Acute or chronic hepatitis, liver cirrhosis and portal hypertension

          -  Synchronous or metachronous malignancy

          -  Severe pulmonary dysfunction

          -  Central nervous system (CNS) invasion

          -  HIV positive

          -  Hepatitis B surface antigen (HBs-Ag) positive

          -  Hepatitis C virus antibody (HCV-Ab) positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomomitsu Hotta, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tokai University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tokai University</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>January 17, 2007</last_update_submitted>
  <last_update_submitted_qc>January 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2007</last_update_posted>
  <keyword>Non-Hodgkin's lymphoma</keyword>
  <keyword>intermediate-grade lymphoma</keyword>
  <keyword>high-grade lymphoma</keyword>
  <keyword>CHOP protocol</keyword>
  <keyword>granulocyte-colony stimulating factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

